Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

Jones, Joanne; Vermersch, Patrick; Bass, Ann D; Boster, Aaron; Montalban Gairín, Xavier; Coles, Alasdair; Traboulsee, Anthony

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Jones, Joanne
dc.contributor.author	Vermersch, Patrick
dc.contributor.author	Bass, Ann D
dc.contributor.author	Boster, Aaron
dc.contributor.author	Montalban Gairín, Xavier
dc.contributor.author	Coles, Alasdair
dc.contributor.author	Traboulsee, Anthony
dc.date.accessioned	2022-06-09T07:23:29Z
dc.date.available	2022-06-09T07:23:29Z
dc.date.issued	2022-04-01
dc.identifier.citation	Coles AJ, Jones JL, Vermersch P, Traboulsee A, Bass AD, Boster A, et al. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Mult Scler J. 2022 Apr 1;28(5):842–846.
dc.identifier.issn	1477-0970
dc.identifier.uri	https://hdl.handle.net/11351/7650
dc.description	Alemtuzumab; Vigilància de productes; Avaluació de riscos
dc.description.sponsorship	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The CAMMS223 and CARE-MS studies, and their extensions, were supported by Sanofi and Bayer Healthcare Pharmaceuticals. Editorial and writing assistance was supported by Sanofi.
dc.language.iso	eng
dc.publisher	SAGE Publications
dc.relation.ispartofseries	Multiple Sclerosis Journal;28(5)
dc.rights	Attribution-NonCommercial 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by-nc/4.0/
dc.source	Scientia
dc.subject	Esclerosi múltiple - Tractament
dc.subject	Avaluació de resultats (Assistència sanitària)
dc.subject	Autoimmunitat
dc.subject.mesh	Multiple Sclerosis
dc.subject.mesh	/drug therapy
dc.subject.mesh	Autoimmunity
dc.subject.mesh	Treatment Outcome
dc.title	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1177/13524585211061335
dc.subject.decs	esclerosis múltiple
dc.subject.decs	/farmacoterapia
dc.subject.decs	autoinmunidad
dc.subject.decs	resultado del tratamiento
dc.relation.publishversion	https://doi.org/10.1177/13524585211061335
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Coles AJ, Jones JL] Department of Clinical Neuroscience, School of Medicine, University of Cambridge, Cambridge, UK. [Vermersch P] Univ. Lille, INSERM UMR-S1172—Lille Neuroscience et Cognition, CHU Lille, FHU Precise, Lille, France. [Traboulsee A] The University of British Columbia, Vancouver, BC, Canada. [Bass AD] Neurology Center of San Antonio, San Antonio, TX, USA. [Boster A] Boster MS Center, Columbus, OH, USA. [Montalban X] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid	34882037
dc.identifier.wos	000729548200001
dc.rights.accessrights	info:eu-repo/semantics/openAccess